Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Maire Gerrard

Managing Editor, Custom Content

London, UK

Maire is the managing editor within Pharma Intelligence’s Custom Content team, supporting clients with their marketing objectives by creating thought leadership content on a wide range of topics that span the drug development process. This content includes articles, research and whitepapers, as well as the delivery of virtual and in-person roundtables. Areas she has covered include clinical trials, manufacturing, regulatory, digitalization and supply chain. An experienced moderator, Maire frequently hosts webinars on these topics and more. Maire holds a Law degree from the University of York and has been based in London since 2017.

Latest From Maire Gerrard

Driving Change In Health Care

Jhaymee Tynan, assistant vice president of integration at Atrium Health and creator and founder of the 100x2030 Initiative, speaks to In Vivo about her journey into health care, putting the patient first, and the importance of encouraging diversity in the industry.

Business Strategies Commercial

Finding Tomorrow’s Biopharma And Medtech CEOs

What are the skills future life sciences leaders will need in order to rise to the top of biopharma and medtech companies? A recent BioTrinity industry panel debated the profile of tomorrow’s leaders.

Business Strategies Commercial

Vivoryon Brings 'Diversity' To Therapeutic Approach In Alzheimer’s

Ulrich Dauer, CEO Vivoryon Therapeutics, the new name for German biotech Probiodrug, talks to In Vivo about introducing more diversity into the Alzheimer’s disease pipeline.

Innovation Clinical Trials
See All